{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:43:29Z","timestamp":1773697409097,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.clml.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T05:41:11Z","timestamp":1348551671000},"page":"438-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["High Response Rate for Treatment With Gemtuzumab Ozogamicin and Cytarabine in Elderly Patients With Acute Myeloid Leukemia and Favorable and Intermediate-I Cytogenetic Risk"],"prefix":"10.1016","volume":"12","author":[{"given":"Sigal","family":"Tavor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einam","family":"Rahamim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadav","family":"Sarid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Rozovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Gibstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Naparstek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.05.007_bib1","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1200\/JCO.2006.10.2731","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older patients","volume":"25","author":"Estey","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.05.007_bib3","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib4","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.05.007_bib5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.05.007_bib6","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","volume":"19","author":"Amadori","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.05.007_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2010.08095.x","article-title":"Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy","volume":"149","author":"Amadori","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.05.007_bib8","doi-asserted-by":"crossref","first-page":"326a","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"Petersdorf","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib9","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.05.007_bib11","doi-asserted-by":"crossref","first-page":"582a","DOI":"10.1182\/blood.V118.21.582.582","article-title":"The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial","volume":"118","author":"Burnett","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib12","doi-asserted-by":"crossref","first-page":"6a","DOI":"10.1182\/blood.V118.21.6.6","volume":"118","author":"Castaigne","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib14","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1182\/blood-2010-09-309229","article-title":"Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin","volume":"117","author":"Fernandez","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.007_bib15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr346","article-title":"Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients","volume":"23","author":"Brunnberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.05.007_bib16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012001346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012001346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:29Z","timestamp":1761870149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012001346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S2152265012001346"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.05.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Response Rate for Treatment With Gemtuzumab Ozogamicin and Cytarabine in Elderly Patients With Acute Myeloid Leukemia and Favorable and Intermediate-I Cytogenetic Risk","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}